Recombinant Human Leptin Treatment Does Not Improve Insulin Action in Obese Subjects With Type 2 Diabetes

Diabetes- United States

doi 10.2337/db10-1302

Full Text

Abstract

Available in

Date

Authors

Publisher

American Diabetes Association

Related search

Different Aetiologies of Type 2 (Non-Insulin-Dependent) Diabetes Mellitus in Obese and Non-Obese Subjects

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
1991English

Vasodilation With Sodium Nitroprusside Does Not Improve Insulin Action in Essential Hypertension

Hypertension
Internal Medicine
1998English

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects With Type 2 Diabetes

Cell Metabolism
Cell BiologyMolecular BiologyPhysiology
2013English

Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2002English

Pcn8 - Severity of Breast Cancer Associated With Type 2 Diabetes and Not With Insulin Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Serum Leptin Concentration in Patients With Type 2 Diabetes

Current Issues in Pharmacy and Medical Sciences
2015English

Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2011English

Acute Alcohol Consumption Improves Insulin Action Without Affecting Insulin Secretion in Type 2 Diabetic Subjects

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2004English

Recombinant DNA Derived Monomeric Insulin Analogue: Comparison With Soluble Human Insulin in Normal Subjects.

BMJ
1988English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy